Incidence of SARS-CoV-2 infection in inflammatory bowel disease
J Gastroenterol Hepatol
.
2020 Nov;35(11):2021-2022.
doi: 10.1111/jgh.15191.
Epub 2020 Aug 3.
Authors
M H Lee
1
,
C H Ng
2
,
Y H Chin
2
,
M Muthiah
2
3
,
F J Foo
4
,
C S Chong
2
5
Affiliations
1
Department of Biological Sciences, Faculty of Science, National University of Singapore, Singapore.
2
Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
3
Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore.
4
Department of General Surgery, Sengkang General Hospital, Singapore.
5
Division of Colorectal Surgery, Department of Surgery, National University Hospital, Singapore.
PMID:
32779774
PMCID:
PMC7404756
DOI:
10.1111/jgh.15191
No abstract available
Publication types
Letter
Meta-Analysis
Systematic Review
MeSH terms
Biological Products / therapeutic use*
COVID-19 / epidemiology*
Humans
Incidence
Inflammatory Bowel Diseases / drug therapy*
SARS-CoV-2
Substances
Biological Products